Bioheart and Ortec target cardiac regeneration:
This article was originally published in Clinica
Executive Summary
Bioheart and Ortec International are collaborating to investigate the combined use of Bioheart's myocelloe heart regeneration product with Ortec's collagen sponge and VEGF releasing Orcel technologies, for regenerating heart muscle in heart attack patients. The companies believe that the complementary therapies may improve bioretention, controlled proliferation and wall thickness mass, and could enhance cardiac angiogenesis and myogenesis. If the research proves successful, it may serve as the basis for new clinical studies, says Bioheart, of Weston, Florida.